Trials / Completed
CompletedNCT04274595
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis: A Proof of Biological Concept Test
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Generic antiretroviral | 200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2021-11-29
- Completion
- 2022-06-20
- First posted
- 2020-02-18
- Last updated
- 2025-12-10
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04274595. Inclusion in this directory is not an endorsement.